CD4 counts and mortality in virologically suppressed US veterans

J Int Assoc Provid AIDS Care. 2014 Mar-Apr;13(2):120-6. doi: 10.1177/2325957413512153. Epub 2013 Dec 30.

Abstract

We used the Veterans Health Administration (VA) HIV Clinical Case Registry (CCR) to evaluate the association between annual CD4 averages and all-cause mortality in HIV-infected veterans during their initial episode of suppressive highly active antiretroviral therapy (HAART). We observed 1083 deaths in 14 769 patients. Unadjusted mortality rates in the top and bottom CD4 quintiles differed significantly from the mid CD4 strata. Mortality in the top CD4 quintile (≥720 cells/mm(3)) was 14.1/1000 patient-years, 95% confidence interval (CI): 10.1-18.2, compared with 20.4 (CI: 15.5-25.3) in the next lower CD4 stratum (530-719 cells/mm(3)). This difference was significant in Cox proportional hazards model, controlling for demographics, hepatitis co-infections, low-level viremia, HAART adherence, and refill rates of individual antiretrovirals (HR: 1.4, CI: 1.13-1.73). Our results support early HAART initiation as advocated by the current US treatment guidelines for HIV infection.

Keywords: CD4 count; HAART; mortality; stavudine; veterans.

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count*
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / immunology
  • HIV Infections / mortality*
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Proportional Hazards Models
  • Registries*
  • Retrospective Studies
  • United States
  • United States Department of Veterans Affairs
  • Veterans / statistics & numerical data*
  • Viral Load

Substances

  • Anti-HIV Agents